Structural biology (SB) provides a critical drug discovery and development tool for accurately identifying and understanding the structure of a target. Alessandro Piai, PhD, Principal Research Scientist at IRBM, describes the company’s expertise in nuclear magnetic resonance (NMR) and how it can be leveraged to accelerate the identification of molecules for progression to the clinic.
Clinical trial is not yet completed, but the distribution of the vaccine is already being organised. AstraZeneca has just signed the first agreements for 400 million doses within September. Everything bodes well for the success of the tests. Piero Di Lorenzo, CEO of IRBM, the Pomezia (Rome)-based company that is collaborating with Oxford, says: “Clinical trial is progressing very well, fingers crossed. There are no problems. If those volunteers already vaccinated don’t develop side effects, the study will be extended to 3.000 people at the end of the month. And we will be ready in September”
Article by Maria Sorbi published on il Giornale – 22/05/2020